Greenwich LifeSciences, Inc. Logo

Greenwich LifeSciences, Inc.

Developing an immunotherapy vaccine to prevent recurrence in HER2-positive breast cancer patients.

GLSI | NDAQ

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
United States of America
Address:
3992 BLUEBONNET DR, BUILDING 14, 77477 STAFFORD
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Greenwich LifeSciences, Inc. is a clinical-stage biopharmaceutical company pioneering the development of GLSI-100 (also known as GP2), an immunotherapy to prevent the recurrence of breast cancer. The company's lead candidate is a peptide-based vaccine designed to activate the immune system to target HER2-positive cancer cells. GLSI-100 is aimed at patients who have undergone surgery and completed standard-of-care treatments. Following a successful Phase IIb trial that showed a significant reduction in recurrence rates and a well-tolerated safety profile, the therapy is now advancing through a global Phase III clinical trial, Flamingo-01. The treatment has been granted Fast Track Designation by the U.S. FDA, highlighting its potential to address a critical unmet need in oncology.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Greenwich LifeSciences, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Greenwich LifeSciences, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Greenwich LifeSciences, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Active Biotech Logo
Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.
Sweden ACTI
ACTUATE THERAPEUTICS, INC. Logo
Clinical-stage biopharma developing a novel GSK-3 inhibitor for hard-to-treat cancers.
United States of America ACTU
AcuCort AB Logo
Develops a rapid oral film for acute allergies, croup, and chemo-induced nausea.
Sweden ACUC
Acurx Pharmaceuticals, Inc. Logo
Developing a new class of antibiotics to treat priority Gram-positive bacterial infections.
United States of America ACXP
Adagene Inc. Logo
Develops novel antibody-based immunotherapies for cancer using an AI-driven discovery platform.
United States of America ADAG
Adaptimmune Therapeutics PLC Logo
Develops novel T-cell therapies to treat solid tumors by engineering a patient's own immune cells.
United States of America ADAP
ADBIOTECH Co.,Ltd. Logo
Develops egg-based IgY antibodies as vaccine/antibiotic alternatives for animal and human health.
South Korea 179530
ADC Therapeutics SA Logo
Develops targeted antibody-drug conjugates for hematological and solid tumors.
United States of America ADCT
Addex Therapeutics Ltd. Logo
Developing novel oral allosteric modulators to treat neurological disorders.
United States of America ADXN
ADIAL PHARMACEUTICALS, INC. Logo
Develops personalized, genetically-targeted drugs for treating Alcohol Use Disorder and addiction.
United States of America ADIL

Talk to a Data Expert

Have a question? We'll get back to you promptly.